KPWS
MNPR icon

Kestra Private Wealth Services’s Monopar Therapeutics MNPR Stock Holding History

Kestra Private Wealth Services’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,691
Closed -$32.6K – 1117
2023
Q1 		$32.6K Buy
+4,691
New +$69.5K ﹤0.01% 1026

Other funds holding MNPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RRCM
Rappaport Reiches Capital Management Skokie`, Illinois $400M AUM 7.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Kestra Private Wealth Services's MNPR Position: Q2 2023 in Review

Kestra Private Wealth Services sold out of Monopar Therapeutics (MNPR) in Q2 2023, closing a stake of 4,691 shares — an estimated $32.6K sold.

Kestra Private Wealth Services first reported a position in MNPR in Q1 2023 and held it in 1 quarter. The position peaked at $32.6K in Q1 2023. 8 funds tracked by Wall St. Rank hold MNPR as of Q2 2023.

  • Kestra Private Wealth Services reported no remaining Monopar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Kestra Private Wealth Services sold 4,691 Monopar Therapeutics shares in Q2 2023, an estimated $32.6K.
  • Kestra Private Wealth Services first reported a position in Monopar Therapeutics in Q1 2023 and held it in 1 quarter.
  • Kestra Private Wealth Services's Monopar Therapeutics position peaked at $32.6K in Q1 2023.
  • 8 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2023.

Based on Kestra Private Wealth Services's 13F filing for Q2 2023, filed 8 Aug 2023.